Abu zahran

Heme -Onc

[Abu zahran @drrifu]

@GunnerPuls Fabregas

[Abu zahran @drrifu]

@FatbearDiaries @FootballOranje_ Better to give chance to kluivert than Memphis

[MV Chandrakanth @ChandrakanthMv]

Can postoperative chemotherapy be omitted in PD-L1–positive resectable gastric cancer?

ASTRUM-006 suggests the answer may be yes.

In patients with PD-L1 CPS ≥5 gastric/GEJ adenocarcinoma, perioperative serplulimab + SOX followed by adjuvant serplulimab (without postoperative chemotherapy) improved EFS compared with standard perioperative SOX.

Key findings:

• CPS ≥10: EFS HR 0.65
• CPS ≥5: EFS HR 0.73
• 2-year EFS: 70% vs 54%
• Grade ≥3 toxicity: 47% vs 59%

A biomarker-selected, chemotherapy-sparing strategy delivered better outcomes with less toxicity.

The most intriguing question:
Is the benefit driven by PD-L1 selection, serplulimab, or elimination of postoperative chemotherapy?

#ASTRUM006 #ASCO2026 #GastricCancer #GIOncology #Immunotherapy #PDL1 #Oncology #MVOnco

[Abu zahran @drrifu]

@_onlyscott Danny alves

[Abu zahran @drrifu]

@UTDMael Iniesta

[Abu zahran @drrifu]

@GunnerPuls Pavel nedved

[Abu zahran @drrifu]

@Gosleepriya 116

[Abu zahran @drrifu]

@UTDMael Jota

[Abu zahran @drrifu]

@utdbravee Samir nasri

[Abu zahran @drrifu]

@UTDIMole Hargreaves

[Abu zahran @drrifu]

@LegacySiu @CFCHaven Guiseppe Rossi

[Abu zahran @drrifu]

@LegacySiu Guiseppe Rossi

[Abu zahran @drrifu]

@UTDMael Case

[Abu zahran @drrifu]

@LegacySiu Fulham

[Abu zahran @drrifu]

@_onlyscott Fulham

[Abu zahran @drrifu]

@TifeRMFC Michael Owen

[Anirban Maitra @Aiims1742]

Despite the many real & painful challenges that remain, 2025 was another year with remarkable advances in #PancreaticCancer research & clinical care. I summarized my list of top ten peer reviewed publications. Apologies to the many deserving papers & authors not here, please add!

[Abu zahran @drrifu]

@Mishi_2210 986

[Dr Rishabh Jain @DrRishabhOnco]

The "Wild West" of post-CDK4/6i HR+/HER2- mBC is finally getting a map. 🗺️

We are moving from empiric sequencing to precision flowcharts.

🔑 Key Pivot: Your 2L choice now depends entirely on ESR1 and PI3K/AKT/PTEN status.

Here is the modern treatment algorithm ⬇️ #SABCS25 #bcsm
@OncoAlert

[Dr Rishabh Jain @DrRishabhOnco]

Doublet vs Triplet in mHSPC: Fast Takeaways 🔍
#GlobalForum25 #PROSCA25

🧬 ADT + ARPI = SOC
Intensify only when biology or volume demands it.

💥 Doublet enough
😊 Metachronous low volume
😊 Elderly low volume
😊 Low risk biology
👉 ADT + ARPI

🔥 Biology driven intensification
🚨 TP53 or RB1 loss
🚨 PTEN loss
🚨 BRCA or HRR mutations
👉 Add docetaxel

💜 Clear Triplet candidates
⚡ De novo high volume
⚡ AR independent or high proliferative biology
👉 Triplet gives strongest OS effect

🌫️ Avoid intensification
🧓 Frail or comorbid
👉 ADT alone or ARPI if tolerated

New Triplets 🆕
🟦 AMPLITUDE: Niraparib
🟩 CAPItello: Capivasertib
🟧 PSMAddition: LuPSMA
Different biology, different triplet.

#OncoTwitter #MedTwitter #ProstateCancer #mHSPC
@oncoalert @asco @myesmo @esmo_open @mirrorsmed